Company intelligence / Profile preview

Thermalin

Newton, Massachusetts, USA

Ownership: Private
Employees: ~23
Development stage: Other

Overview

Thermalin is developing multiple next-generation insulin analogs, including glucose-responsive and ultra-stable insulins. The company has reached prototype-ready stages and partnered some programs with Sanofi; the clinical development status appears pre-clinical to early-stage with substantial research collaboration.

Therapeutic areas: Endocrinology
Modalities: ProteinRecombinant proteinBiologic
Industry: Biotech

Partnerships

Sanofi

Beyond the preview

Go deeper on Thermalin.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Thermalin.

Explore the full profile